Your browser doesn't support javascript.
loading
Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.
Morgan, Alexandra R; Parker, Geoff J M; Roberts, Caleb; Buonaccorsi, Giovanni A; Maguire, Niall C; Hubbard Cristinacce, Penny L; Singh, Dave; Vestbo, Jørgen; Bjermer, Leif; Jögi, Jonas; Taib, Ziad; Sarv, Janeli; Bruijnzeel, Piet L B; Olsson, Lars E; Bondesson, Eva; Nihlén, Ulf; McGrath, Deirdre M; Young, Simon S; Waterton, John C; Nordenmark, Lars H.
Afiliación
  • Morgan AR; Bioxydyn Ltd, Manchester, UK; Centre for Imaging Sciences and Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK. Electronic address: alex.morgan@bioxydyn.com.
  • Parker GJ; Bioxydyn Ltd, Manchester, UK; Centre for Imaging Sciences and Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
  • Roberts C; Bioxydyn Ltd, Manchester, UK; Centre for Imaging Sciences and Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
  • Buonaccorsi GA; Bioxydyn Ltd, Manchester, UK.
  • Maguire NC; Bioxydyn Ltd, Manchester, UK.
  • Hubbard Cristinacce PL; Centre for Imaging Sciences and Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
  • Singh D; University of Manchester, Medicines Evaluation Unit, Manchester Academic Health Sciences Centre, University Hospital of South Manchester, Manchester, UK.
  • Vestbo J; University of Manchester, Medicines Evaluation Unit, Manchester Academic Health Sciences Centre, University Hospital of South Manchester, Manchester, UK.
  • Bjermer L; Department of Respiratory Medicine & Allergology, Skåne University Hospital, Lund, Sweden.
  • Jögi J; Department of Clinical Physiology, Skåne University Hospital and Lund University, Lund, Sweden.
  • Taib Z; AstraZeneca R&D, Mölndal, Sweden.
  • Sarv J; AstraZeneca R&D, Mölndal, Sweden.
  • Bruijnzeel PL; AstraZeneca R&D, Mölndal, Sweden.
  • Olsson LE; AstraZeneca R&D, Mölndal, Sweden.
  • Bondesson E; AstraZeneca R&D, Mölndal, Sweden.
  • Nihlén U; Department of Respiratory Medicine & Allergology, Skåne University Hospital, Lund, Sweden; AstraZeneca R&D, Mölndal, Sweden.
  • McGrath DM; Centre for Imaging Sciences and Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.
  • Young SS; AstraZeneca R&D, Alderley Park, UK.
  • Waterton JC; Centre for Imaging Sciences and Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK; AstraZeneca R&D, Alderley Park, UK.
  • Nordenmark LH; AstraZeneca R&D, Mölndal, Sweden.
Eur J Radiol ; 83(11): 2093-101, 2014 Nov.
Article en En | MEDLINE | ID: mdl-25176287
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Broncodilatadores / Imagen por Resonancia Magnética / Corticoesteroides / Budesonida / Enfermedad Pulmonar Obstructiva Crónica / Fumarato de Formoterol Tipo de estudio: Clinical_trials / Evaluation_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Radiol Año: 2014 Tipo del documento: Article Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Broncodilatadores / Imagen por Resonancia Magnética / Corticoesteroides / Budesonida / Enfermedad Pulmonar Obstructiva Crónica / Fumarato de Formoterol Tipo de estudio: Clinical_trials / Evaluation_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Radiol Año: 2014 Tipo del documento: Article Pais de publicación: Irlanda